Description

Oxaliplatin is a third-generation platinum-based antineoplastic agent, widely recognized for its critical role in modern chemotherapy regimens. Its primary commercial value lies in its efficacy against colorectal cancer, particularly in combination therapies, offering a vital treatment option for a major global health challenge. This active pharmaceutical ingredient (API) is essential for pharmaceutical manufacturers, research institutions, and compounding facilities engaged in oncology drug development and production.

Application

• Oncology Pharmaceutical Manufacturing: Primary use as the active pharmaceutical ingredient (API) in injectable formulations for the treatment of metastatic colorectal cancer.
• Combination Chemotherapy: Key component in the FOLFOX (folinic acid, fluorouracil, and oxaliplatin) and XELOX (capecitabine and oxaliplatin) regimens, which are standard-of-care protocols.
• Pharmaceutical Research & Development (R&D): Used in preclinical and clinical studies for investigating new cancer treatment protocols and combination strategies.
• Generic Drug Production: Serves as the core compound for manufacturers producing generic versions of branded oxaliplatin therapies.
• Hospital & Clinical Pharmacy Compounding: Utilized in specialized settings for preparing patient-specific doses where commercial formulations are not suitable.
• Academic & Biomedical Research: Employed in laboratory studies to understand mechanisms of platinum-drug activity, resistance, and DNA damage repair pathways.

Basic Information

Product Name	Oxaliplatin
CAS No.	63121-00-6
Molecular Formula	C8H14N2O4Pt
Molecular Weight	397.29 g/mol
Synonyms	1,2-Diaminocyclohexane Oxalatoplatinum; Eloxatin® (Brand Name); Dacplat; Oxalatoplatinum; L-OHP; (SP-4-2)-[(1R,2R)-1,2-Cyclohexanediamine-N,N'][ethanedioato(2-)-O,O']platinum; (1R,2R)-Cyclohexane-1,2-diamine; ethanedioate; platinum
EINECS	Contact for details

Quality Control

Our Oxaliplatin is manufactured under strict quality management systems, with specifications designed to meet or exceed major pharmacopoeial standards such as USP and EP. Every batch undergoes comprehensive analytical testing including HPLC for assay and impurity profiling, residual solvent analysis, and specific tests for related substances. A Certificate of Analysis (COA) documenting purity, identity, and safety parameters is provided with each shipment to ensure full traceability and regulatory compliance for our global B2B clients.

Storage

Preserve in a tightly closed container, protected from light. Store at controlled room temperature, 15-25°C (59-77°F), or as specified on the label. The product is hygroscopic (moisture-sensitive) and must be kept in a dry environment. For long-term stability, consider storage under inert atmosphere.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to reference standard
Identification (HPLC)	Retention time corresponds to reference
Assay (HPLC)	98.0% - 102.0% (on anhydrous basis)
Water Content (KF)	≤ 2.0%
Related Substances (HPLC)	Individual impurity: ≤ 0.5% Total impurities: ≤ 2.0%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Heavy Metals	≤ 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.